Rein Verbeke
Ghent University
Messenger RNACancerInnate immune systemAntigenCellCytotoxic T cellChemistryIn vitroImmunologyIn vivoVaccinationT cellTumor microenvironmentInflammationImmunotherapyDendritic cellPancreatic isletsCancer immunotherapyImmunogenicitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cancer researchTransfectionMedicineBiologyImmune systemCell biology
28Publications
8H-index
214Citations
Publications 26
Newest
#1An-Katrien Minnaert (UGent: Ghent University)H-Index: 3
#2Helena Vanluchene (UGent: Ghent University)H-Index: 1
Last. Katrien Remaut (UGent: Ghent University)H-Index: 28
view all 8 authors...
The recent approval of messenger RNA (mRNA)-based vaccines to combat the SARS-CoV-2 pandemic highlights the potential of both conventional mRNA and self-amplifying mRNA (saRNA) as a flexible immunotherapy platform to treat infectious diseases. Besides the antigen it encodes, mRNA itself has an immune-stimulating activity that can contribute to vaccine efficacy. This self-adjuvant effect, however, will interfere with mRNA translation and may influence the desired therapeutic outcome. To further e...
Source
#2Lien De BeckH-Index: 1
Last. Karine BreckpotH-Index: 3
view all 7 authors...
#1Linde Schoenmaker (LEI: Leiden University)H-Index: 1
#2Dominik Witzigmann (UBC: University of British Columbia)H-Index: 20
Last. Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
view all 7 authors...
Abstract A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we discuss proposed structures of mRNA-LNPs, factors that impact mRNA-LNP stability and strategies to optimize mRNA-LNP product stability. Analysis of mRNA-LNP st...
Source
#1Rein Verbeke (UGent: Ghent University)H-Index: 8
#2Ine Lentacker (UGent: Ghent University)H-Index: 28
Last. Heleen Dewitte (UGent: Ghent University)H-Index: 18
view all 4 authors...
In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for emergency use, while another mRNA vaccine, CVnCoV, progressed to phase 3 clinical testing. The COVID-19 mRNA vaccines represent a new class of vaccine products, which consist of synthetic mRNA strands encoding the SARS-CoV-2 Spike glycoprotein, packaged in lipid nanoparticles to deliver mRNA to cells. This review digs deeper into th...
Source
#1Lien Van Hoecke (UGent: Ghent University)H-Index: 12
#2Rein Verbeke (UGent: Ghent University)H-Index: 8
Last. Sandra Van Lint (UGent: Ghent University)H-Index: 18
view all 7 authors...
mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature's core building blocks carrying important information and can be considered as a powerful vector for delivery of therapeutic proteins to the patient.For a long time, the major focus in the use of in vitro transcribed mRNA was on development of cancer vaccines, ...
Source
#1Laurens RaesH-Index: 6
#2Stephan StremerschH-Index: 15
Last. Kevin BraeckmansH-Index: 69
view all 15 authors...
Efficient and safe cell engineering by transfection of nucleic acids remains one of the long-standing hurdles for fundamental biomedical research and many new therapeutic applications, such as CAR T cell-based therapies. mRNA has recently gained increasing attention as a more safe and versatile alternative tool over viral- or DNA transposon-based approaches for the generation of adoptive T cells. However, limitations associated with existing nonviral mRNA delivery approaches hamper progress on g...
Source
#1Lien Van Hoecke (UGent: Ghent University)H-Index: 12
#2Rein Verbeke (UGent: Ghent University)H-Index: 8
Last. Xavier Saelens (UGent: Ghent University)H-Index: 59
view all 11 authors...
Abstract To date, mRNA-based biologics have mainly been developed for prophylactic and therapeutic vaccination to combat infectious diseases or cancer. In the past years, optimization of the characteristics of in vitro transcribed mRNA has led to significant reduction of the inflammatory responses. Thanks to this, mRNA therapeutics have entered the field of passive immunization. Here, we established an mRNA treatment that is based on mRNA that codes for a bispecific single-domain antibody constr...
Source
#1Thomas ErtveldtH-Index: 1
#2Sofie Meulewaeter (UGent: Ghent University)
Last. Karine BreckpotH-Index: 53
view all 10 authors...
#1Shweta Saini (Katholieke Universiteit Leuven)H-Index: 3
#2Jennifer Poelmans (Katholieke Universiteit Leuven)H-Index: 8
Last. Uwe Himmelreich (Katholieke Universiteit Leuven)H-Index: 52
view all 15 authors...
Abstract The fungus Aspergillus fumigatus is ubiquitous in nature and the most common cause of invasive pulmonary aspergillosis (IPA) in patients with a compromised immune system. The development of IPA in patients under immunosuppressive treatment or in primary immunodeficiency patients demonstrates the importance of the host immune response in controlling aspergillosis. However, study of the host-microbe interaction has been hampered by the lack of tools for their non-invasive assessment. We d...
Source
#1Rein Verbeke (UGent: Ghent University)H-Index: 8
#2Ine Lentacker (UGent: Ghent University)H-Index: 28
Last. Heleen Dewitte (Vrije Universiteit Brussel)H-Index: 18
view all 4 authors...
Abstract In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for vaccination. In the following decades, an improved understanding of the mRNA pharmacology, together with novel insights in immunology have positioned mRNA-based technologies as next-generation vaccines. This review outlines the history and current state-of-the-art in mRNA vaccination, while presenting an immunological view on mRNA vaccine development. As such, we highlight the challenges in v...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.